Unknown

Dataset Information

0

Plasma Glycated CD59, a Novel Biomarker for Detection of Pregnancy-Induced Glucose Intolerance.


ABSTRACT: Plasma glycated CD59 (pGCD59) is an emerging biomarker in diabetes. We assessed whether pGCD59 could predict the following: the results of the glucose challenge test (GCT) for screening of gestational diabetes mellitus (GDM) (primary analysis); and the diagnosis of GDM and prevalence of large for gestational age (LGA) newborns (secondary analyses).Case-control study of 1,000 plasma samples from women receiving standard prenatal care, 500 women having a normal GCT (control subjects) and 500 women with a failed GCT and a subsequent oral glucose tolerance test (case patients).Compared with control subjects, the median (interquartile range) pGCD59 value was 8.5-fold higher in case patients and 10-fold higher in GDM patients, as follows: control subjects 0.33 (0.19); case patients 2.79 (1.4); GDM patients 3.23 (1.43) (P < 0.001); area under the receiver operating characteristic curve 0.92. LGA prevalence was 4.3% in the lowest quartile and 13.5% in the highest quartile of pGCD59.One pGCD59 measurement during weeks 24-28 identifies pregnancy-induced glucose intolerance with high sensitivity and specificity and can potentially identify the risk for LGA.

SUBMITTER: Ghosh P 

PROVIDER: S-EPMC5481979 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Plasma Glycated CD59, a Novel Biomarker for Detection of Pregnancy-Induced Glucose Intolerance.

Ghosh Pamela P   Luque-Fernandez Miguel A MA   Vaidya Anand A   Ma Dongdong D   Sahoo Rupam R   Chorev Michael M   Zera Chloe C   McElrath Thomas F TF   Williams Michelle A MA   Seely Ellen W EW   Halperin Jose A JA  

Diabetes care 20170427 7


<h4>Objective</h4>Plasma glycated CD59 (pGCD59) is an emerging biomarker in diabetes. We assessed whether pGCD59 could predict the following: the results of the glucose challenge test (GCT) for screening of gestational diabetes mellitus (GDM) (primary analysis); and the diagnosis of GDM and prevalence of large for gestational age (LGA) newborns (secondary analyses).<h4>Research design and methods</h4>Case-control study of 1,000 plasma samples from women receiving standard prenatal care, 500 wome  ...[more]

Similar Datasets

| S-EPMC8511340 | biostudies-literature
| S-EPMC9021770 | biostudies-literature
| S-EPMC3775575 | biostudies-literature
| S-EPMC7082084 | biostudies-literature
| S-EPMC4198481 | biostudies-literature
| S-EPMC2551649 | biostudies-literature
| S-EPMC8433413 | biostudies-literature
| S-EPMC6508637 | biostudies-literature
| S-EPMC5040052 | biostudies-literature
| S-EPMC9659665 | biostudies-literature